According to IMS Health, Mylan has currently 117 ANDAs pending FDA approval, representing $82.1 billion in annual brand sales.
Moreover, IMS also said that 35 of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales.
Mylan is a diversified generics and specialty pharmaceutical company that operates a specialty business focused on respiratory and allergy therapies.